Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityNo recent work listed

Hongzhe Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0002-8398-1870; OpenAlex author ID A5101962040. Sources: OpenAlex.

Their work

Papers
7 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2017: 3 papers · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper

Papers 7

  1. Health-related quality of life and survival outcomes for patients with major depressive disorder and anxiety: A longitudinal study in pancreatic ductal adenoca… Co-author DOI 10.1002/cam4.6577↗
  2. Cystatin B increases autophagic flux by sustaining proteolytic activity of cathepsin B and fuels glycolysis in pancreatic cancer: CSTB orchestrates autophagy a… Co-author DOI 10.1002/ctm2.1126↗
  3. Immunity-Related Gene Signature Identifies Subtypes Benefitting From Adjuvant Chemotherapy or Potentially Responding to PD1/PD-L1 Blockage in Pancreatic Cancer. First author DOI 10.3389/fcell.2021.682261↗
  4. Melittin-induced long non-coding RNA NONHSAT105177 inhibits proliferation and migration of pancreatic ductal adenocarcinoma. First author DOI 10.1038/s41419-018-0965-3↗
  5. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2017.04.012↗
  6. Long noncoding RNA NORAD, a novel competing endogenous RNA, enhances the hypoxia-induced epithelial-mesenchymal transition to promote metastasis in pancreatic … Co-author DOI 10.1186/s12943-017-0738-0↗
  7. Integrated expression profiles analysis reveals novel predictive biomarker in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.16732↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Baiyong Shen · 6 shared papers, 2017–2023 · strength 0.57
  2. Hao Chen · 4 shared papers, 2017–2022 · strength 0.38
  3. Chenghong Peng · 5 shared papers, 2017–2021 · strength 0.38
  4. Xiongxiong Lu · 4 shared papers, 2017–2021 · strength 0.31
  5. Xinjing Wang · 4 shared papers, 2017–2018 · strength 0.27
  6. Zhen Huo · 4 shared papers, 2017–2018 · strength 0.27
  7. Xiaomei Tang · 3 shared papers, 2017–2021 · strength 0.24
  8. Yuan Fang · 3 shared papers, 2017–2018 · strength 0.20
  9. Chenlei Wen · 3 shared papers, 2017–2018 · strength 0.20
  10. Yuchen Ji · 1 shared paper, 2023 · strength 0.19
  11. Yiran Zhou · 1 shared paper, 2023 · strength 0.19
  12. Haoda Chen · 1 shared paper, 2023 · strength 0.19
  13. Weishen Wang · 2 shared papers, 2017–2021 · strength 0.18
  14. Xiaxing Deng · 2 shared papers, 2017–2021 · strength 0.17
  15. Xiaxing Deng · 2 shared papers, 2017–2018 · strength 0.14
  16. Cheng Xiong · 1 shared paper, 2022 · strength 0.14
  17. Lijie Han · 1 shared paper, 2022 · strength 0.14
  18. Yongsheng Jiang · 1 shared paper, 2022 · strength 0.14
  19. Lingxi Jiang · 1 shared paper, 2022 · strength 0.14
  20. Youwei Zhu · 1 shared paper, 2022 · strength 0.14
  21. Yan‐Miao Huo · 1 shared paper, 2022 · strength 0.14
  22. Meilin Xue · 1 shared paper, 2022 · strength 0.14
  23. Baiyong Shen · 1 shared paper, 2022 · strength 0.14
  24. Hao Qian · 1 shared paper, 2021 · strength 0.11
  25. Dongfeng Cheng · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.